Professor of Therapeutics-Cardiology at the University of Lorraine. Doctor of Medicine, Doctor of Human Biology (PhD), Clinical Pharmacology (University of Lyon and Oxford).
Current functions
Consultant at the Inserm Clinical Investigation Centre (CIC).
Main Contributions
Establishment of a heart failure care network in Lorraine. Author of major advances in the field of mineralocorticoids, leading to changes in therapeutic practices (IA Recommendations) to prolong survival in heart failure.
Research areas
Heart failure, Aldosterone, Fibrosis, Biomarkers, Clinical Trials, Hypertension. He coordinates several EU FP7: Heart failure Omics and AGEing (HOMAGE), FIBRosis as a TARGET in Heart Failure (FIBROTARGETS), French-German ANR. FOCUS-MR. WP leader EU FP7 (The MEtabolic Road to DIAstolic Heart Failure (MEDIA), FHU CARTAGE and RHU FIGHT-HF, Nancy.
He holds several patents in the field of biomarkers. Co-founder of "CardioRenal, Sarl", a telemedicine start-up. Founder and organiser of the CVCT forum "Global CardioVascular Clinical Trialists Forum(www.globalcvctforum.com) with Inserm, US-NHLBI, EMA and FDA, since 2003, and now in Washington DC.
Awards
In 1981, he was awarded the CNRS prize for young scientists in clinical pharmacology for his research in cardiovascular pharmacology1.
In 1983, he was awarded the Paul-Neumann Prize in Clinical Pharmacology1.
In 2014, he was awarded the Paul-Milliez Prize for his work on hypertension11.
In 2015, he became the first doctor in the history of Tunisia to enter the Thomson Reuters list of most cited researchers12. He maintained his place in this ranking in 2016 and 201712.
Learned Societies
Former President of the French Society of Hypertension (2007-2008); Former President of the Working Group on Pharmacology and Drug Therapy of the European Society of Cardiology (2008-2010); Participates in numerous Editorial Boards of scientific journals.
As of 30/10/2016, he is the author of 573 publications, 81218 citations, and his Hirsch Index is 85.